Insmed Inc. (INSM)
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.7 per share versus the Zacks Consensus Estimate of a loss of $1.3. This compares to a loss of $1.94 per share a year ago.
Insmed (INSM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Insmed (INSM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Insmed Stock Overvalued After The 45% Jump?
Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What's driving this surge?
United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock
United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Insmed's treprostinil based product seemingly edged United's Tyvaso on key measures such as pulmonary vascular resistance and 6-minute walk test. United's PAH products account for >90% of its revenues and it already faces a threat from Liquidia's Yutrepia.
Insmed Stock Jumps 29% on Encouraging PAH Study Results
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
Insmed: Company Presses On With Further POC PAH Treatment Data
Insmed achieved positive phase 2b results for TPIP in PAH, meeting all endpoints and paving the way for phase 3 trials in 2025-2026. The global pulmonary arterial hypertension market is expected to reach $12.2 billion by 2032. Brensocatib's NDA for bronchiectasis is under Priority Review, with a PDUFA date of August 12, 2025, targeting an untapped market.
Insmed shares surge on positive trial results for pulmonary arterial hypertension therapy
Insmed Incorporated (NASDAQ:INSM) shares surged more than 27% after the company unveiled positive results from a Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The randomized, double-blind, placebo-controlled study met its primary endpoint as well as all secondary efficacy endpoints.
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects
Examine the evolution of Insmed's (INSM) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago.
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
